Menu
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, CerebroFlo®, Certas® Plus, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MatriStem UBMTM, MediHoney®, MicroFrance®, PriMatrix®, SurgiMend®, TCC-EZ®, and VersaTru®.
1100 Campus Road
Princeton, New Jersey 08540
Phone: 16092750500
www.integralife.com
Integra LifeSciences (NASDAQ: IART ) reported upbeat second-quarter earnings and lowered its FY24 guidance below estimates on Monday . Integra Lifesciences posted adjusted earnings of 63 cents per share, beating market estimates of 62 cents per share. The company''s quarterly sales came in at $418.175 million topping expectations of $413.154 million, according to data from Benzinga Pro . “Our second quarter financial performance continues to reflect the persistent market demand for our diversified portfolio and the commitment of our teams,” said Jan De Witte, Integra LifeSciences’ president and chief executive officer. “Using the learnings from our Boston facility, we are continuing a thorough analysis of our operations and are committed to enhancing the quality, … Full story available on Benzinga.com
No summary available.
https://www.investing.com/news/company-news/citi-downgrades-integra-lifesciences-stock-amid-compliance-and-revenue-concerns-93CH-3542937
https://www.investing.com/news/company-news/integra-lifesciences-downgraded-to-sell-despite-betterthanexpected-results-93CH-3542425
Integra LifeSciences (IART) Faces Steep Decline Due to Downside Guidance and Quality Issues
NEW YORK (AP) — Stocks that traded heavily or had substantial price changes on Monday: ON Semiconductor Corp. (ON), up $9.69 to $79.86. The semiconductor components maker beat analysts’ fiscal second-quarter earnings and revenue forecasts. Inspire Medical Systems Inc. (INSP), up $5.45 to $131.24. The sleep apnea treatment system maker raised its revenue forecast for the year. Revvity Inc. (RVTY), up $7.37 to $122.52. The maker of scientific instruments beat analysts’ second-quarter financial forecasts. Guardant Health Inc. (GH), up $1.16 to $34.16. The FDA approved the cancer testing company’s Shield blood test for colon cancer screening. Crown Holdings Inc. (CCK), up $1.28 to $86.96. The packaging company announced a $2 billion stock buyback program. Integra LifeSciences Holdings Corp. (IART), down $5.42 to $26.01. The medical device maker cut its earnings forecast for the year. Enstar Group Ltd. (ESGR), down $22.81 to $325.50. A group led by Sixth Street will buy the investment holding company for about $5.1 billion.
Q2 revenue and earnings beats didn''t make up for the company''s full-year guidance cut.
No summary available.
Integra Lifesciences (NASDAQ: IART ) just reported results for the second quarter of 2024. Integra Lifesciences reported earnings per share of 63 cents. This was above the analyst estimate for EPS of 62 cents. The company reported revenue of $418.18 million. This was 1.22% better than the analyst estimate for revenue of $413.15 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post IART Stock Earnings: Integra Lifesciences Beats EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
